Many Wegovy Users Pause Treatment, Some Resume Within Months
A Danish cohort study of over 157,000 first-time semaglutide users for obesity found that 49% discontinued within a year, with discontinuation rising steadily over time. Among those who stopped, about 25% restarted within three months, suggesting frequent temporary interruptions or self-adjusted dosing. Higher discontinuation risk was seen in younger adults, men, and those with lower income or prior psychiatric medication use.
The study tracked over 157,000 Danish adults without diabetes who first used semaglutide for obesity, defining discontinuation as a 60-day prescription gap. Discontinuation rose steadily: 13% by three months, 27% by six, 39% by nine, reaching 49% at one year. Among those who stopped, roughly 25% resumed within three months, hinting at intermittent use or dose adjustments rather than permanent cessation. Researchers noted that no subgroup had a discontinuation risk below 41%, even after adjusting for age and sex. Higher risks appeared in younger adults, men, lower-income residents, and those with prior psychiatric or gastrointestinal medication use, as well as certain chronic conditions.
This pattern could reshape how clinicians and insurers approach obesity care, as long-term adherence is central to sustained weight loss and metabolic benefits. If many patients pause or stop early—especially younger or lower-income individuals—real-world effectiveness may fall short of clinical trial results. This may also influence coverage decisions, patient counseling on costs and side effects, and the design of support programs. Ultimately, the findings could prompt more realistic expectations and tailored follow-up, though broader access and affordability remain unresolved challenges.